In response to the article, "Medical Devices Driving Up Heart Care Costs", see link, I could not help but have a problem with it. Here was my shared comment on Google Reader: I abhor simplistic analyses. The increased cost of treating coronary artery disease has gone up 1.5% per year (after adjustment for inflation) and [...]
The market for coronary stents in Asia and the Pacific region contains principally China (early technology adopters) and Japan (with a longer regulatory approval cycle), which generate roughly 200,000 in stent sales annually. The area is, in the aggregate, the second biggest market for coronary stent sales globally. While China commands much attention due to [...]
With medtech investment in January 2010 already clocked at $180 million in five days, the month and year are off to a quick start. The financing amounts are also bigger, with over 70% of the financing rounds thus far in excess of $20 million each. The financings include: Intuity Medical: $64 million CircuLite, Inc.: [...]
There are some obvious trends and dynamics in medtech: Cost is now a central driver of much development – either as an advantage to be marketed (e.g., reduced recovery time) or as an upper limiter of features offered. Changes in the cost of doing business: demands for post-market surveillance, change in approval process (510K), physician [...]
The medical device sector is expected to "outperform" in 2010, according to Leerink Swan (http://www.massdevice.com/news/analyst-medical-device-sector-should-outperform-2010), resulting in top line growth of 7% and bottom line growth of 11%. The industry will see a progressive easing of the constraint on hospital inventory purchases that have limited sales since 2008. This will result in sales increases [...]
In the course of a week, two separate surveys of the medtech industry have confirmed that executives foresee business in 2010 moving positively, but without an abundance of optimism — or effort. The Emergo Group survey of 1,000 medtech executives illustrated results similar to the smaller, anecdotal Tatum LLC, survey, which indicated that, in 2010, [...]
In a relatively classic scenario, established technologies have seen a loss of their once-premium pricing while emerging technologies are able to command an increasing premium as reward for their sophistication. The worldwide coronary stent market is following the predicted course. Bare metal stents have been on the market for more than a decade and have, [...]
A recent survey of medical technology industry executives by Atlanta-based executive services firm Tatum LLC, as reported in The Journal of New England Technology, revealed a tone of “cautious optimism” among the group as they looked out over the next couple months: Almost two-thirds of those executives surveyed — 40 in total — said they expected [...]
Medical technology venture capital financings for the month of November 2009 (to date) have had a good start, totaling over $170 million in the first two weeks. Noteworthy financings include $30 million by Entelleus Medical (treatment of sinusitis), $30 million by Fate Therapeutics (induced pluripotent stem cells), $27 million by Spinal Modulation (devices for treatment [...]
Medical technology financings for the month of October stood at $202 million, marking the third month in a row that financings have declined, from a high in 2009 of $440 million in July. See financings by month for September, August and July and for 2009 trend. We track medical technology, in our biased definition, as medical [...]
Contact:
